ctx310 - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,823 +0.60%

DJIA 48,242 +0.70%

Nasdaq 25,035 +0.57%

DAX 23,863 -0.42%

Gold $4,196 +0.16%

Oil $98.24 +1.60%

BTC $71,900 +0.75%

VIX 20.63 -15.03%

EUR/USD 1.1785 -0.02%

ETH $2,208 -0.02%

S&P 500 6,823 +0.60%

DJIA 48,242 +0.70%

Nasdaq 25,035 +0.57%

DAX 23,863 -0.42%

Gold $4,196 +0.16%

Oil $98.24 +1.60%

BTC $71,900 +0.75%

VIX 20.63 -15.03%

EUR/USD 1.1785 -0.02%

ETH $2,208 -0.02%

ctx310

High-tech cardiology lab visualizing CRISPR Therapeutics Pipeline gene edits for cholesterol and Lp(a).

CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk

By Maik Kemper • Apr 8, 2026

High-tech cardiology lab visualizing CRISPR Therapeutics Pipeline gene edits for cholesterol and Lp(a).

CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk

By Maik Kemper • Apr 8, 2026

Can the CRISPR Therapeutics Pipeline in cardiology turn today’s modest gene-editing revenues into a multi-billion-dollar growth story? Maik Kemper Editor in Chief Conclusion In summary,…